Yoo C, Shin SH, Park JO, Kim KP, Jeong JH, Ryoo BY, et al. Current status and future perspectives of perioperative therapy for resectable biliary tract cancer: a multidisciplinary review. Cancers. 2021;13(7):1647.

Article  PubMed  PubMed Central  Google Scholar 

Patel N, Benipal B. Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states. Cureus. 11(1):e3962

Cancer of the Liver and Intrahepatic Bile Duct - Cancer Stat Facts. SEER. Available from: https://seer.cancer.gov/statfacts/html/livibd.html. Accessed 27 July 2022.

Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729245.

Article  PubMed  PubMed Central  Google Scholar 

Turati F, Bertuccio P, Negri E, Vecchia CL. Epidemiology of cholangiocarcinoma. Hepatoma. Research. 2022;12(8):19.

Google Scholar 

Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, et al. Surgery for cholangiocarcinoma. Liver Int. 2019;39(Suppl Suppl 1):143–55.

Article  PubMed  PubMed Central  Google Scholar 

Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wang XW, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2019;69(4):1803–15.

Article  PubMed  Google Scholar 

Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.

Article  CAS  PubMed  Google Scholar 

Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation. JAMA Oncol. 2021;7(11):1–10.

Article  PubMed Central  Google Scholar 

Oh DY, Ruth HA, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence. 2022;1(8):EVIDoa2200015.

Article  Google Scholar 

Valle JW, Kelley RK, Nervi B, Do-Youn O, Zhu AX. Biliary tract cancer. The Lancet. 2021;397(10272):428–44.

Article  CAS  Google Scholar 

NCCN Guidelines Version 5.2021. Available from: https://www.nccn.org/guidelines/guidelines-detail. Accessed 20 Feb 2022. Most recent NCCN guideline supports the role of locoregional regional therapies in the treatment of unresectable or metastatic intrahepatic cholangiocarcinoma.

Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;9(1):44–54.

Article  PubMed  Google Scholar 

Madoff DC, Gaba RC, Weber CN, Clark TWI, Saad WE. Portal venous interventions: state of the art. Radiology. 2016;278(2):333–53.

Article  PubMed  Google Scholar 

Mosconi C, Calandri M, Javle M, Odisio BC. Interventional radiology approaches for intra-hepatic cholangiocarcinoma. Chin Clin Oncol. 2020;9(1):8.

Article  PubMed  Google Scholar 

Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One. 2014;9(3):e90929.

Article  PubMed  PubMed Central  Google Scholar 

Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.

Article  PubMed  Google Scholar 

Okabayashi T, Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Takayama T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer. 2001;92(9):2374–83.

Article  CAS  PubMed  Google Scholar 

Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg. 2003;10(4):288–91.

Article  PubMed  Google Scholar 

Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16(1):14–22.

Article  PubMed  Google Scholar 

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.

Article  PubMed  Google Scholar 

Fong ZV, Brownlee SA, Qadan M, Tanabe KK. The Clinical management of cholangiocarcinoma in the United States and Europe: a comprehensive and evidence-based comparison of guidelines. Ann Surg Oncol. 2021;28(5):2660–74.

Article  PubMed  Google Scholar 

Jin S, Fu Q, Wuyun G, Wuyun T. Management of post-hepatectomy complications. World J Gastroenterol. 2013;19(44):7983–91.

Article  PubMed  PubMed Central  Google Scholar 

Asencio JM, Vaquero J, Olmedilla L, García Sabrido JL. “Small-for-flow” syndrome: shifting the “size” paradigm. Med Hypotheses. 2013;80(5):573–7.

Article  CAS  PubMed  Google Scholar 

de Graaf W, van Lienden KP, Dinant S, Roelofs JJTH, Busch ORC, Gouma DJ, et al. Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection. J Gastrointest Surg. 2010;14(2):369–78.

Article  PubMed  Google Scholar 

Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002;137(6):675–80; discussion 680–681.

Madoff DC, Hicks ME, Abdalla EK, Morris JS, Vauthey JN. Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness—study in 26 patients. Radiology. 2003;227(1):251–60.

Article  PubMed  Google Scholar 

May BJ, Talenfeld AD, Madoff DC. Update on portal vein embolization: evidence-based outcomes, controversies, and novel strategies. J Vasc Interv Radiol. 2013;24(2):241–54.

Article  PubMed  Google Scholar 

Zhang J, Steib CJ. New evidence for liver venous deprivation: safety and feasibility for extended liver resections. Ann Transl Med. 2020;8(19):1259.

Article  PubMed  PubMed Central  Google Scholar 

Kobayashi K, Yamaguchi T, Denys A, Perron L, Halkic N, Demartines N, et al. Liver venous deprivation compared to portal vein embolization to induce hypertrophy of the future liver remnant before major hepatectomy: a single center experience. Surgery. 2020;167(6):917–23.

Article  PubMed  Google Scholar 

Heil J, Schadde E. Simultaneous portal and hepatic vein embolization before major liver resection. Langenbecks Arch Surg. 2021;406(5):1295–305.

Article  PubMed  Google Scholar 

Böning G, Fehrenbach U, Auer TA, Neumann K, Jonczyk M, Pratschke J, et al. Liver Venous Deprivation (LVD) Versus portal vein embolization (PVE) alone prior to extended hepatectomy: a matched pair analysis. Cardiovasc Intervent Radiol [Internet]. 2022 Mar 21 [cited 2022 Apr 10]; Available from. https://doi.org/10.1007/s00270-022-03107-0

Deshayes E, Piron L, Bouvier A, Lapuyade B, Lermite E, Vervueren L, et al. Study protocol of the HYPER-LIV01 trial: a multicenter phase II, prospective and randomized study comparing simultaneous portal and hepatic vein embolization to portal vein embolization for hypertrophy of the future liver remnant before major hepatectomy for colo-rectal liver metastases. BMC Cancer. 2020;20(1):574.

Article  PubMed  PubMed Central  Google Scholar 

•• Korenblik R, Olij B, Bemelmans MHA, Binkert C, van der Leij C, Wang X, et al. Training, implementation, and safety evaluation of portal and hepatic vein embolization (PVE/HVE) to accelerate FLR hypertrophy – first worldwide DRAGON 1 experience. HPB. 2021;1(23):S740–1. First multicenter, prospective randomized study to compare the efficacy of LVD vs. PVE in liver hypertrophy in patients liver metastases from colorectal cancer currently with 25 centers involved with preliminary results improved resectability and liver hypertrophy.

Article  Google Scholar 

Vanichapol T, Leelawat K, Hongeng S. Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signal-regulated kinase signaling pathway. Mol Med Rep. 2015;12(3):3265–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sweeney J, Parikh N, El-Haddad G, Kis B. Ablation of intrahepatic cholangiocarcinoma. Semin Intervent Radiol. 2019;36(4):298–302.

Article  PubMed  PubMed Central  Google Scholar 

Crocetti L, de Baére T, Pereira PL, Tarantino FP. CIRSE standards of practice on thermal ablation of liver tumours. Cardiovasc Intervent Radiol. 2020;43(7):951–62.

Article  PubMed  Google Scholar 

Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol. 2015;26(7):943–8.

Article  PubMed  Google Scholar 

Chu HH, Kim JH, Shin YM, Won HJ, Kim PN. Percutaneous radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection: multivariable analysis of factors predicting survival outcomes. Am J Roentgenol. 2021;217(2):426–32.

Article  Google Scholar 

Brandi G, Rizzo A, Dall’Olio FG, Felicani C, Ercolani G, Cescon M, et al. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. Int J Hyperth. 2020;37(1):479–85.

Article  Google Scholar 

Kim JH, Won HJ, Shin YM, Kim KA, Kim PN. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol. 2011;196(2):W205-209.

Article  PubMed  Google Scholar 

Carrafiello G, Laganà D, Cotta E, Mangini M, Fontana F, Bandiera F, et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc Intervent Radiol. 2010;33(4):835–9.

Article  PubMed